By Clare Grace, Chief Patient Officer
The average length of a clinical study cycle is on the rise and has been for decades. Look at any five-year period: cycles are seven to 10 percent longer than in the five years immediately prior.
That’s according to Ken Getz, director of the Tufts Center for the Study of Drug Development (Tufts CSDD). When we had the opportunity to co-present at DIA 2021, Getz offered insights into three factors driving up average study duration: executional complexity, hyper-customization, and operating fragmentation.